Needham analysts downgraded Hologic stock from a Buy to a Hold rating, citing multiple challenges that could impede the company's revenue and profit growth in the calendar year 2025 (CY25). The ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...